Skip to content
10-K

Annual Report

Kiromic Biopharma, Inc.

0001437749-25-004000

← back to feed
Filed
Feb 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 10, 2025 1.53M sh
Capex FY 2024 · Dec 31, 2024 $366K
Capex restated FY 2024 · Dec 31, 2023 $207K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$19.46M
Operating Cash Flow restated FY 2024 · Dec 31, 2023 −$21.23M
Cash And Equivalents FY 2024 · Dec 31, 2024 $1.14M
Cash And Equivalents FY 2024 · Dec 31, 2023 $3.2M
Stockholders Equity FY 2024 · Dec 31, 2024 −$12.59M
Stockholders Equity restated FY 2024 · Dec 31, 2023 −$9.12M
Stockholders Equity restated FY 2024 · Dec 31, 2022 −$5.78M
Current Liabilities FY 2024 · Dec 31, 2024 $20.9M
Current Liabilities restated FY 2024 · Dec 31, 2023 $20.38M
Total Liabilities FY 2024 · Dec 31, 2024 $21.13M
Total Liabilities restated FY 2024 · Dec 31, 2023 $21.29M
Current Assets FY 2024 · Dec 31, 2024 $3.3M
Current Assets FY 2024 · Dec 31, 2023 $4.43M
Total Assets FY 2024 · Dec 31, 2024 $8.55M
Total Assets FY 2024 · Dec 31, 2023 $12.17M
Sga Expense FY 2024 · Dec 31, 2024 $8.85M
Sga Expense restated FY 2024 · Dec 31, 2023 $10.31M
Rd Expense FY 2024 · Dec 31, 2024 $6.85M
Rd Expense restated FY 2024 · Dec 31, 2023 $6.95M
Net Income FY 2024 · Dec 31, 2024 −$26.9M
Net Income restated FY 2024 · Dec 31, 2023 −$20.95M
Operating Income FY 2024 · Dec 31, 2024 −$23.77M
Operating Income restated FY 2024 · Dec 31, 2023 −$19.94M
Revenue FY 2024 · Dec 31, 2024 $0